Protein kinase activity decreases with higher braak stages of Alzheimer's disease pathology

Journal of Alzheimer's Disease

Volumn 49, Issue 4, 2015, Pages 927-943

  Rosenberger, Andrea F N ^a   Hilhorst, Riet ^b   Coart, Elisabeth ^c   Barrado, Leandro García ^c   Naji, Faris ^b   Rozemuller, Annemieke J M ^a   Van Der Flier, Wiesje M ^a   Scheltens, Philip ^a   Hoozemans, Jeroen J M ^a   Van Der Vies, Saskia M ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b PamGene International BV   (Netherlands)

^c INTERNATIONAL DRUG DEVELOPMENT INSTITUTE   (Belgium)

Author keywords

Alzheimer's disease; peptide microarray analysis; phospho peptides; postmortem changes; protein kinase activity; signaling pathways

Indexed keywords

EPHRIN RECEPTOR A1; FYN ASSOCIATED TYROSINE KINASE; PROTEIN KINASE; PROTEIN KINASE FES; PROTEIN SERINE THREONINE KINASE; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE 6; TYROSINE; UNCLASSIFIED DRUG;

ADULT; AGE; AGED; ALZHEIMER DISEASE; ARTICLE; BRAIN ANALYSIS; BRAIN WEIGHT; CEREBROSPINAL FLUID PH; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE DURATION; DISEASE SEVERITY; DOWN REGULATION; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME PHOSPHORYLATION; FEMALE; GENOTYPE; HIPPOCAMPAL TISSUE; HUMAN; HUMAN TISSUE; MALE; ONCOGENE SRC; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; SEX DIFFERENCE; SIGNAL TRANSDUCTION; TISSUE LEVEL; VERY ELDERLY; COHORT ANALYSIS; ENZYMOLOGY; HIPPOCAMPUS; METABOLISM; MIDDLE AGED; PATHOLOGY; PHOSPHORYLATION; SEVERITY OF ILLNESS INDEX;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; COHORT STUDIES; FEMALE; HIPPOCAMPUS; HUMANS; MALE; MIDDLE AGED; PHOSPHORYLATION; PROTEIN KINASES; PROTEIN-SERINE-THREONINE KINASES; SEVERITY OF ILLNESS INDEX;

EID: 84953716010     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-150429     Document Type: Article

References (88)

1. Bateman RJ, Xiong C, Benzinger TLS, Fagan AM, Goate A, Fox NC, Marcus DS, Cairns NJ, Xie X, Blazey TM, Holtzman DM, Santacruz A, Buckles V, Oliver A, Moulder K, Aisen PS, Ghetti B, Klunk WE, McDade E, Martins RN, Masters CL, Mayeux R, Ringman JM, Rossor MN, Schofield PR, Sperling RA, Salloway S, Morris JC. (2012). Clinical, and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med. 367, 795-804.
2. Caselli RJ, Reiman EM. (2013). Characterizing the preclinical stages of Alzheimer's disease, and the prospect of presymptomatic intervention. J Alzheimers Dis 33(Suppl 1), S405-S416.
3. Chung S-H. (2009). Aberrant phosphorylation in the pathogenesis of Alzheimer's disease. BMB Rep. 42, 467-474.
4. Olariu A, Yamada K, NabeshimaT(2005) Amyloid pathology, and protein kinase C (PKC): Possible therapeutics effects of PKC activators. J Pharmacol Sci. 97, 1-5.
5. Tagawa K, Homma H, Saito A, Fujita K, Chen X, Imoto S, Oka T, Ito H, Motoki K, Yoshida C, Hatsuta H, Murayama S, Iwatsubo T, Miyano S, Okazawa H. (2015). Comprehensive phosphoproteome analysis unravels the core signaling network that initiates the earliest synapse pathology in preclinical Alzheimer's disease brain. Hum Mol Genet. 24, 540-558.
6. Hanger DP, Anderton BH, NobleW(2009) Tau phosphorylation: The therapeutic challenge for neurodegenerative disease. Trends Mol Med. 15, 112-119.
7. Martins-De-Souza D, Guest PC, Vanattou-Saifoudine N, Rahmoune H, Bahn S. (2012). Phosphoproteomic differences in major depressive disorder postmortem brains indicate effects on synaptic function. Eur Arch Psychiatry Clin Neurosci. 262, 657-666.
8. Hilhorst R, Houkes L, van den Berg A, Ruijtenbeek R. (2009). Peptide microarrays for detailed, high-Throughput substrate identification, kinetic characterization, and inhibition studies on protein kinase A. Anal Biochem. 387, 150-161.
9. Sikkema AH, Diks SH, den Dunnen WF, ter Elst A, Scherpen FJ, Hoving EW, Ruijtenbeek R, Boender PJ, de Wijn R, Kamps WA, Peppelenbosch MP, de Bont ES. (2009). Kinome profiling in pediatric brain tumors as a new approach for target discovery. Cancer Res. 69, 5987-5995.
10. McCullumsmith RE, Hammond JH, Shan D, Meador-Woodruff JH. (2014). Postmortem brain: An underutilized substrate for studying severe mental illness. Neuropsychopharmacology. 39, 65-87.
11. Hollingworth P, Harold D, Sims R, Gerrish A, Lambert JC, Carrasquillo MM, Abraham R, Hamshere ML, Pahwa JS, Moskvina V, Dowzell K, Jones N, Stretton A, Thomas C, Richards A, Ivanov D, Widdowson C, Chapman J, Lovestone S, Powell J, Proitsi P, Lupton MK, Brayne C, Rubinsztein DC, Gill M, Lawlor B, Lynch A, Brown KS, Passmore PA, Craig D, McGuinness B, Todd S, Holmes C, Mann D, Smith AD, Beaumont H, Warden D, Wilcock G, Love S, Kehoe PG, Hooper NM, Vardy ER, Hardy J, Mead S, Fox NC, Rossor M, Collinge J, Maier W, Jessen F, Rüther E, Schürmann B, Heun R, Kölsch H, van den Bussche H, Heuser I, Kornhuber J, Wiltfang J, Dichgans M, Frölich L, Hampel H, Gallacher J, Hüll M, Rujescu D, Giegling I, Goate AM, Kauwe JS, Cruchaga C, Nowotny P, Morris JC, Mayo K, Sleegers K, Bettens K, Engelborghs S, De Deyn PP, Van Broeckhoven C, Livingston G, Bass NJ, Gurling H, McQuillin A, Gwilliam R, Deloukas P, Al-Chalabi A, Shaw CE, Tsolaki M, Singleton AB, Guerreiro R, Mühleisen TW, Nöthen MM, Moebus S, Jöckel KH, Klopp N, ichmann HE, Pankratz VS, Sando SB, Aasly JO, Barcikowska M, Wszolek ZK, Dickson DW, Graff-Radford NR, Petersen RC, van Duijn CM, Breteler MM, Ikram MA, DeStefano AL, Fitzpatrick AL, Lopez O, Launer LJ, Seshadri S, Berr C, Campion D, Epelbaum J, Dartigues JF, Tzourio C, Alpérovitch A, Lathrop M, Feulner TM, Friedrich P, Riehle C, Krawczak M, Schreiber S, Mayhaus M, Nicolhaus S, Wagenpfeil S, Steinberg S, Stefansson H, Stefansson K, Snaedal J, Björnsson S, Jonsson PV, Chouraki V, Genier-Boley B, Hiltunen M, Soininen H, Combarros O, Zelenika D, Delepine M, Bullido MJ, Pasquier F, Mateo I, Frank-Garcia A, Porcellini E, Hanon O, Coto E, Alvarez V, Bosco P, Siciliano G, Mancuso M, Panza F, Solfrizzi V, Nacmias B, Sorbi S, Bossù P, Piccardi P, Arosio B, Annoni G, Seripa D, Pilotto A, Scarpini E, Galimberti D, Brice A, Hannequin D, Licastro F, Jones L, Holmans PA, Jonsson T, Riemenschneider M, Morgan K, Younkin SG, Owen MJ, O'Donovan M, Amouyel P, Williams J. (2011). Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33, and CD2AP are associated with Alzheimer's disease. Nat Genet. 43, 429-435.
12. Morgan K. (2011). The three new pathways leading to Alzheimer's disease. Neuropathol Appl Neurobiol. 37, 353-357.
13. Lu YM. (1998). Src activation in the induction of longterm potentiation in CA1 hippocampal neurons. Science. 279, 1363-1368.
14. Kalia LV, Gingrich JR, Salter MW. (2004). Src in synaptic transmission, and plasticity. Oncogene. 23, 8007-8016.
15. Yamaguchi H, Haga C, Hirai S, Nakazato Y, Kosaka K. (1990). Distinctive, rapid, and easy labeling of diffuse plaques in the Alzheimer brains by a new methenamine silver stain. Acta Neuropathol. 79, 569-572.
16. Thal DR, Rüb U, Schultz C, Sassin I, Ghebremedhin E, Del Tredici K, Braak E, Braak H. (2000). Sequence of Abeta-protein deposition in the human medial temporal lobe. J Neuropathol Exp Neurol. 59, 733-748.
17. Braak H, Alafuzoff I, Arzberger T, Kretzschmar H, Del Tredici K. (2006). Staging of Alzheimer disease-Associated neurofibrillary pathology using paraffin sections, and immunocytochemistry. Acta Neuropathol. 112, 389-404.
18. Reisberg B, Ferris SH, De Leon MJ, Crook T. (1982). The global deterioration scale for assessment of primary degenerative dementia. Am J Psychiatry. 139, 1136-1139.
19. Hilhorst R, Houkes L, Mommersteeg M, Musch J, van den Berg A, Ruijtenbeek R. (2013). Peptide microarrays for profiling of serine/threonine kinase activity of recombinant kinases, and lysates of cells, and tissue samples. Methods Mol Biol. 977, 259-271.
20. Sikkema AH, Diks SH, den Dunnen WF, ter Elst A, Scherpen FJ, Hoving EW, Ruijtenbeek R, Boender PJ, de Wijn R, Kamps WA, Peppelenbosch MP, de Bont ES. (2009). Kinome profiling in pediatric brain tumors as a new approach for target discovery. Cancer Res. 69, 5987-5995.
21. Versele M, Talloen W, Rockx C, Geerts T, Janssen B, Lavrijssen T, King P, Göhlmann HWH, Page M, Perera T. (2009). Response prediction to a multitargeted kinase inhibitor in cancer cell lines, and xenograft tumors using high-content tyrosine peptide arrays with a kinetic readout. Mol Cancer Ther. 8, 1846-1855.
22. Franceschini A, Szklarczyk D, Frankild S, Kuhn M, Simonovic M, Roth A, Lin J, Minguez P, Bork P, von Mering C, Jensen LJ (2013)STRINGv9.1: Protein-protein interaction networks, with increased coverage, and integration. Nucleic Acids Res. 41, D808-D815.
23. Keshava Prasad TS, Goel R, Kandasamy K, Keerthikumar S, Kumar S, Mathivanan S, Telikicherla D, Raju R, Shafreen B, Venugopal A, Balakrishnan L, Marimuthu A, Banerjee S, Somanathan DS, Sebastian A, Rani S, Ray S, Harrys Kishore CJ, Kanth S, Ahmed M, Kashyap MK, Mohmood R, Ramachandra YL, Krishna V, Rahiman BA, Mohan S, Ranganathan P, Ramabadran S, Chaerkady R, Pandey A. (2009). Human Protein Reference Database-2009 update. Nucleic Acids Res. 37, D767-D772.
24. Matthews L, Gopinath G, Gillespie M, Caudy M, Croft D, de Bono B, Garapati P, Hemish J, Hermjakob H, Jassal B, Kanapin A, Lewis S, Mahajan S, May B, Schmidt E, Vastrik I, Wu G, Birney E, Stein L, D'eustachio P. (2009). Reactome knowledgebase of human biological pathways, and processes. Nucleic Acids Res. 37, D619-D622.
25. Hunter T, Sefton BM. (1980). Transforming gene product of Rous sarcoma virus phosphorylates tyrosine. Proc Natl Acad Sci U S A. 77, 1311-1315.
26. Korolainen MA, Nyman TA, Aittokallio T, Pirttilä T. (2010). An update on clinical proteomics in Alzheimer's research. J Neurochem. 112, 1386-1414.
27. Hoozemans JJM, Hilhorst R, Ruijtenbeek R, Rozemuller AJM, Van Der Vies SM. (2012). Protein kinase activity profiling of postmortem human brain tissue. Neurodegener Dis. 10, 46-48.
28. Hoozemans JJM, Haastert ES, Van, Mulder SD, Nielsen HM, Veerhuis R, Ruijtenbeek R, Rozemuller AJM, Hilhorst R, Van Der Vies SM. (2014). Increased IRAK-4 kinase activity in Alzheimer's disease; Inhibitory effect of IRAK-1/4 inhibitor I on pro-inflammatory cytokine secretion but not on uptake of amyloid beta by human glial cells. J Clin Cell Immunol. 5, 243.
29. McGuire JL, Hammond JH, Yates SD, Chen D, Haroutunian V, Meador-Woodruff JH, McCullumsmith RE. (2014). Altered serine/threonine kinase activity in schizophrenia. Brain Res. 1568, 42-54.
30. Bratland A, Boender PJ, Høifødt HK, Østensen IHG, Ruijtenbeek R, Wang M-Y, Berg JP, Lilleby W, Fodstad Ø, Ree AH. (2009). Osteoblast-induced EGFR/ERBB2 signaling in androgen-sensitive prostate carcinoma cells characterized by multiplex kinase activity profiling. Clin Exp Metastasis. 26, 485-496.
31. Li X, Greenwood AF, Powers R, Jope RS. (1996). Effects of postmortem interval, age, and Alzheimer's disease on G-proteins in human brain. Neurobiol Aging. 17, 115-122.
32. Li X, Friedman AB, Roh MS, Jope RS. (2005). Anesthesia, and post-mortem interval profoundly influence the regulatory serine phosphorylation of glycogen synthase kinase-3 in mouse brain. J Neurochem. 92, 701-704.
33. O'Callaghan JP, Sriram K. (2004). Focused microwave irradiation of the brain preserves in vivo protein phosphorylation: Comparison with other methods of sacrifice, and analysis of multiple phosphoproteins. J Neurosci Methods. 135, 159-168.
34. Funk KE, Kuret J. (2012). Lysosomal fusion dysfunction as a unifying hypothesis for Alzheimer's disease pathology. Int J Alzheimers Dis. 2012, 752894.
35. Oka T, Tagawa K, Ito H, OkazawaH(2011) Dynamic changes of the phosphoproteome in postmortem mouse brains. PLoS One. 6, e21405.
36. Mertins P, Yang F, Liu T, Mani DR, Petyuk VA, Gillette MA, Clauser KR, Qiao JW, Gritsenko MA, Moore RJ, Levine DA, Townsend R, Erdmann-Gilmore P, Snider JE, Davies SA, Ruggles KV, Fenyo D, Kitchens RT, Li S, Olvera N, Dao F, Rodriguez H, Chan DW, Liebler D, White F, Rodland KD, Mills GB, Smith RD, Paulovich AG, Ellis M, Carr SA. (2014). Ischemia in tumors induces early, and sustained phosphorylation changes in stress kinase pathways but does not affect global protein levels. Mol Cell Proteomics. 13, 1690-1704.
37. Kingsbury AE, Foster OJ, Nisbet AP, Cairns N, Bray L, Eve DJ, Lees AJ, Marsden CD. (1995). Tissue pH as an indicator of mRNA preservation in human post-mortem brain. Brain Res Mol Brain Res. 28, 311-318.
38. Hardy JA, Wester P, Winblad B, Gezelius C, Bring G, Eriksson A. (1985). The patients dying after long terminal phase have acidotic brains; implications for biochemical measurements on autopsy tissue. J Neural Transm. 61, 253-264.
39. Mexal S, Berger R, Adams CE, Ross RG, Freedman R, Leonard S. (2006). Brain pH has a significant impact on human postmortem hippocampal gene expression profiles. Brain Res. 1106, 1-11.
40. Johnston NL, Cervenak J, Shore AD, Torrey EF, Yolken RH. (1997). Multivariate analysis of RNA levels from postmortem human brains as measured by three different methods of RT-PCR. Stanley Neuropathology Consortium. J Neurosci Methods. 77, 83-92.
41. Harrison PJ, Heath PR, Eastwood SL, Burnet PW, McDonald B, Pearson RC. (1995). The relative importance of premortem acidosis, and postmortem interval for human brain gene expression studies: Selective mRNA vulnerability, and comparison with their encoded proteins. Neurosci Lett. 200, 151-154.
42. Webb BA, Chimenti M, Jacobson MP, Barber DL. (2011). Dysregulated pH: Aperfect storm for cancer progression. Nat Rev Cancer. 11, 671-677.
43. Monoranu CM, Apfelbacher M, Grünblatt E, Puppe B, Alafuzoff I, Ferrer I, Al-Saraj S, Keyvani K, Schmitt A, Falkai P, Schittenhelm J, Halliday G, Kril J, Harper C, McLean C, Riederer P, Roggendorf W. (2009). PH measurement as quality control on human post mortem brain tissue: A study of the BrainNet Europe consortium. Neuropathol Appl Neurobiol. 35, 329-337.
44. Heras-Sandoval D, Avila-Muñoz E, Arias C. (2011). The phosphatidylinositol 3-kinase/mTor pathway as a therapeutic target for brain aging, and neurodegeneration. Pharmaceuticals. 4, 1070-1087.
45. Heras-Sandoval D, Pérez-Rojas JM, Hernández-Damián J, Pedraza-Chaverri J. (2014). The role of PI3K/AKT/mTOR pathway in the modulation of autophagy, and the clearance of protein aggregates in neurodegeneration. Cell Signal. 26, 2694-2701.
46. Haugabook SJ, Le T, Yager D, Zenk B, Healy BM, Eckman EA, Prada C, Younkin L, Murphy P, Pinnix I, Onstead L, Sambamurti K, Golde TE, Dickson D, Younkin SG, Eckman CB. (2001). Reduction of Abeta accumulation in the Tg2576 animal model of Alzheimer's disease after oral administration of the phosphatidyl-inositol kinase inhibitorwortmannin. FASEB J. 15, 16-18.
47. Bhaskar K, Miller M, Chludzinski A, Herrup K, Zagorski M, Lamb BT. (2009). The PI3K-Akt-mTOR pathway regulates Abeta oligomer induced neuronal cell cycle events. Mol Neurodegener. 4, 14.
48. Perluigi M, Pupo G, Tramutola A, Cini C, Coccia R, Barone E, Head E, Butterfield DA, Di Domenico F. (2014). Neuropathological role of PI3K/Akt/mTORaxis inDownsyndrome brain. Biochim Biophys Acta. 1842, 1144-1153.
49. DeKosky ST, Scheff SW(1990) Synapse loss in frontal cortex biopsies in Alzheimer's disease: Correlation with cognitive severity. Ann Neurol. 27, 457-464.
50. Terry RD, Masliah E, Salmon DP, Butters N, DeTeresa R, Hill R, Hansen LA, Katzman R. (1991). Physical basis of cognitive alterations in Alzheimer's disease: Synapse loss is the major correlate of cognitive impairment. Ann Neurol. 30, 572-580.
51. Griffin RJ, Moloney A, Kelliher M, Johnston JA, Ravid R, Dockery P, O'Connor R, O'Neill C. (2005). Activation of Akt/PKB, increased phosphorylation of Akt substrates, and loss, and altered distribution of Akt, and PTEN are features of Alzheimer's disease pathology. J Neurochem. 93, 105-117.
52. Horwood JM, Dufour F, Laroche S, Davis S. (2006). Signalling mechanisms mediated by the phosphoinositide 3-kinase/Akt cascade in synaptic plasticity, and memory in the rat. Eur J Neurosci. 23, 3375-3384.
53. Bruel A, Cherqui G, Columelli S, Margelin D, Roudier M, Sinet PM, Prieur M, Pérignon JL, Delabar J. (1991). Reduced protein kinase C activity in sporadic Alzheimer's disease fibroblasts. Neurosci Lett. 133, 89-92.
54. Hong M, Lee VM. (1997). Insulin, and insulin-like growth factor-1 regulate tau phosphorylation in cultured human neurons. J Biol Chem. 272, 19547-19553.
55. Huang C, Lee C, Hsu K. (2009). The role of insulin receptor signaling in synaptic plasticity, and cognitive function. Chang Gung Med J. 33, 115-125.
56. Nelson TJ, Sun MK, Hongpaisan J, Alkon DL. (2008). Insulin, PKC signaling pathways, and synaptic remodeling during memory storage, and neuronal repair. Eur J Pharmacol. 585, 76-87.
57. Salter MW. (1998). Src, N-methyl-D-Aspartate (NMDA) receptors, and synaptic plasticity. Biochem Pharmacol. 56, 789-798.
58. Malenka RC, Nicoll RA. (1999). Long-Term potentiation-A decade of progress? Science. 285, 1870-1874.
59. Girault JA, Costa A, Derkinderen P, Studler JM, Toutant M. (1999). FAK, and PYK2/CAKbeta in the nervous system: A link between neuronal activity, plasticity, and survival? Trends Neurosci. 22, 257-263.
60. Inoue E, Deguchi-Tawarada M, Togawa A, Matsui C, Arita K, Katahira-Tayama S, Sato T, Yamauchi E, Oda Y, Takai Y. (2009). Synaptic activity prompts gamma-secretase-mediated cleavage of EphA4, and dendritic spine formation. J Cell Biol. 185, 551-564.
61. Yamaguchi Y, Pasquale EB. (2004). Eph receptors in the adult brain. Curr Opin Neurobiol. 14, 288-296.
62. Rosenberger A, Rozemuller A, van der Flier WM, Scheltens P, van der Vies SM, Hoozemans J. (2014). Altered distribution of the EphA4 kinase in hippocampal brain tissue of patients with Alzheimer's disease correlates with pathology. Acta Neuropathol Commun. 2, 79.
63. Simón AM, de Maturana RL, Ricobaraza A, Escribano L, Schiapparelli L, Cuadrado-Tejedor M, Pérez-Mediavilla A, Avila J, Del Río J, Frechilla D. (2009). Early changes in hippocampal Eph receptors precede the onset of memory decline in mouse models of Alzheimer's disease. J Alzheimers Dis. 17, 773-786.
64. Salter MW, Kalia LV. (2004). Src kinases: A hub for NMDA receptor regulation. Nat Rev Neurosci. 5, 317-328.
65. Iimoto DS, Masliah E, Deteresa R, Terry RD, Saitoh T. (1990). Aberrant casein kinase II in Alzheimer's disease. Brain Res. 507, 273-280.
66. Chung HJ, Huang YH, Lau L-F, Huganir RL. (2004). Regulation of the NMDA receptor complex, and trafficking by activity-dependent phosphorylation of theNR2BsubunitPDZ ligand. J Neurosci. 24, 10248-10259.
67. Kimura R, Matsuki N. (2008). Protein kinase CK2 modulates synaptic plasticity by modification of synaptic NMDA receptors in the hippocampus. J Physiol. 586, 3195-3206.
68. Walter J, Schindzielorz a, Hartung B, Haass C. (2000). Phosphorylation of the beta-Amyloid precursor protein at the cell surface by ectocasein kinases. 1, and 2. J Biol Chem. 275, 23523-23529.
69. Lenzken SC, Stanga S, Lanni C, De Leonardis F, Govoni S, Racchi M. (2010). Recruitment of casein kinase 2 is involved in AbetaPP processing following cholinergic stimulation. J Alzheimers Dis. 20, 1133-1141.
70. Raftery M, Campbell R, Glaros EN, Rye K-A, Halliday GM, Jessup W, Garner B. (2005). Phosphorylation of apolipoprotein-E at an atypical protein kinase CK2 PSD/E site in vitro. Biochemistry. 44, 7346-7353.
71. Baum L, Masliah E, Iimoto DS, Hansen LA, Halliday WC, SaitohT(1992) Casein kinase II is associated with neurofibrillary tangles but is not an intrinsic component of paired helical filaments. Brain Res. 573, 126-132.
72. Lim ACB, Tiu S-Y, Li Q, Qi RZ. (2004). Direct regulation of microtubule dynamics by protein kinase CK2. J Biol Chem. 279, 4433-4439.
73. De Felice FG, Vieira MNN, Bomfim TR, Decker H, Velasco PT, Lambert MP, Viola KL, Zhao W-Q, Ferreira ST, Klein WL(2009) Protection of synapses against Alzheimer's-linked toxins: Insulin signaling prevents the pathogenic binding of Abeta oligomers. Proc Natl Acad Sci U S A. 106, 1971-1976.
74. Schwab C, McGeer PL. (2008). Inflammatory aspects of Alzheimer disease, and other neurodegenerative disorders. J Alzheimers Dis. 13, 359-369.
75. Verkhratsky A, Rodríguez JJ, Parpura V. (2013). Astroglia in neurological diseases. Future Neurol. 8, 149-158.
76. Dhawan G, Floden AM, Combs CK. (2012). Amyloid- oligomers stimulate microglia through a tyrosine kinase dependent mechanism. Neurobiol Aging. 33, 2247-2261.
77. Eikelenboom P, Bate C, Van Gool WA, Hoozemans JJM, Rozemuller JM, Veerhuis R, Williams A. (2002). Neuroinflammation in Alzheimer's disease, and prion disease. Glia. 40, 232-239.
78. Zhang Z, Wu Z, Zhu X, Hui X, Pan J, Xu Y. (2014). Hydroxysafflor yellow A inhibits neuroinflammation mediated by A1-42 in BV-2 cells. Neurosci Lett. 562, 39-44.
79. Babus LW, Little EM, Keenoy KE, Minami SS, Chen E, Song JM, Caviness J, Koo SY, Pak DTS, Rebeck GW, Turner RS, Hoe HS. (2011). Decreased dendritic spine density, and abnormal spine morphology in Fyn knockout mice. Brain Res. 1415, 96-102.
80. Laurent CE, Smithgall TE. (2004). The c-Fes tyrosine kinase cooperates with the breakpoint cluster region protein (Bcr) to induce neurite extension in a Rac-, and Cdc42-dependent manner. Exp Cell Res. 299, 188-198.
81. Lucke-Wold BP, Turner RC, Logsdon AF, Simpkins JW, Alkon DL, Smith KE, Chen YW, Tan Z, Huber JD, Rosen CL. (2015). Common mechanisms of Alzheimer's disease, and ischemic stroke: The role of protein kinase C in the progression of age-related neurodegeneration. J Alzheimers Dis. 43, 711-724.
82. Zheng Y, Gierut J, Wang Z, Miao J, Asara JM, Tyner AL. (2013). Protein tyrosine kinase 6 protects cells from anoikis by directly phosphorylating focal adhesion kinase, and activating AKT. Oncogene. 32, 4304-4312.
83. Mizuguchi Y, Specht S, Isse K, Sasatomi E, Lunz JG, Takizawa T, Demetris AJ. (2015). Breast tumor kinase/protein tyrosine kinase 6 (Brk/PTK6) activity in normal, and neoplastic biliary epithelia. J Hepatol. 63, 399-407.
84. Carmena M, Ruchaud S, Earnshaw WC. (2009). Making the Auroras glow: Regulation of Aurora A, and B kinase function by interacting proteins. Curr Opin Cell Biol. 21, 796-805.
85. Mahadevan D, Bearss DJ, Vankayalapati H. (2003). Structurebased design of novel anti-cancer agents targeting aurora kinases. Curr Med Chem Anticancer Agents. 3, 25-34.
86. Juhász G, Földi I, Penke B. (2011). Systems biology of Alzheimer's disease: How diverse molecular changes result in memory impairment in AD. Neurochem Int. 58, 739-750.
87. Klafki HW, Staufenbiel M, Kornhuber J, Wiltfang J. (2006). Therapeutic approaches to Alzheimer's disease. Brain. 129, 2840-2855.
88. Schneider LS, Mangialasche F, Andreasen N, Feldman H, Giacobini E, Jones R, Mantua V, Mecocci P, Pani L, Winblad B, KivipeltoM(2014) Clinical trials, and late-stage drug development for Alzheimer's disease: An appraisal from 1984 to 2014. J Intern Med. 275, 251-283.